☆ 4.7 Article

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, Research & Experimental

Novel insights into the SPOP E3 ubiquitin ligase: From the regulation of molecular mechanisms to tumorigenesis

Xian-Miao Li et al.

Summary: Ubiquitin-mediated protein degradation is a crucial process for maintaining protein homeostasis in eukaryotic cells. SPOP, as a substrate adaptor of the CRL3 family, has garnered attention for its versatility in regulatory pathways and involvement in various tumor types. Abnormalities in SPOP can disrupt downstream biological processes and promote tumorigenesis, while liquid-liquid phase separation may play a role in the interaction between SPOP and its substrates.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

RIG-I Promotes Cell Viability, Colony Formation, and Glucose Metabolism and Inhibits Cell Apoptosis in Colorectal Cancer by NF-κB Signaling Pathway

Yangyang Liu et al.

Summary: This study revealed the role of RIG-I in colorectal cancer, including regulation of cell proliferation, apoptosis, and glucose metabolism, mediated at least partly through the NF-kappa B signaling pathway.

DISEASE MARKERS (2022)

Add to Collection

Article Oncology

CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein

Min Dong et al.

Summary: The study found that CUL3 can promote the degradation of PD-L1 protein by forming a complex with SPOP, thereby inhibiting immune escape and increasing chemosensitivity in ovarian cancer cells.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors

Yuan Wei et al.

Summary: The PD-1/PD-L1 axis is a crucial target for anti-tumor immunity in cancer patients, with potential for durable remission. However, challenges remain in broadening application, guiding personalized therapeutic strategies, and improving clinical responses. PD-L1 expression is regulated by multiple factors, with the host immune microenvironment playing a key role in determining clinical efficacy.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Add to Collection

Review Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow et al.

Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1

Xiaozhen Zhang et al.

Summary: The study reveals that NEK2 phosphorylates PD-L1 to maintain stability, impacting the efficacy of immunotherapy in pancreatic cancer, while NEK2 deficiency enhances lymphocyte infiltration and sensitivity to immunotherapy. Inhibiting NEK2 can enhance PD-L1 blockade, potentially improving the effectiveness of pancreatic cancer treatment.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Immunology

The inflammatory pathogenesis of colorectal cancer

Mark Schmitt et al.

Summary: The research on colorectal cancer indicates the importance of an inflammatory microenvironment for tumorigenesis, which influences the activation of immune cells and stromal cells, as well as the role of intestinal microbiome in tumor development. Chronic inflammation can initiate tumorigenesis, and tumor-elicited and therapy-induced inflammation are also implicated in promoting colorectal cancer.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Epigenetics of colorectal cancer: biomarker and therapeutic potential

Gerhard Jung et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Oncology

Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma

Yong Li et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration

Hussein Sultan et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Review Cell Biology

PD-L1 degradation pathway and immunotherapy for cancer

Qian Gou et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Review Immunology

Tumour-intrinsic resistance to immune checkpoint blockade

Anusha Kalbasi et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Correction Engineering, Biomedical

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours (vol 3, pg 306, 2019)

Han Yao et al.

NATURE BIOMEDICAL ENGINEERING (2019)

Add to Collection

Article Immunology

RIG-I activation is critical for responsiveness to checkpoint blockade

Simon Heidegger et al.

SCIENCE IMMUNOLOGY (2019)

Add to Collection

Review Immunology

Interferon target-gene expression and epigenomic signatures in health and disease

Franck J. Barrat et al.

NATURE IMMUNOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

Jinfang Zhang et al.

NATURE (2018)

Add to Collection

Review Cell Biology

RIG-I: a multifunctional protein beyond a pattern recognition receptor

Xiao-xiao Xu et al.

PROTEIN & CELL (2018)

Add to Collection

Review Immunology

Regulation and Function of the PD-L1 Checkpoint

Chong Sun et al.

IMMUNITY (2018)

Add to Collection

Review Oncology

Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy

Jung-Mao Hsu et al.

CANCER RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel et al.

NATURE (2017)

Add to Collection

Review Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

Sandip Pravin Patel et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Add to Collection

Article Biochemistry & Molecular Biology

SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression

Wenjian Gan et al.

MOLECULAR CELL (2015)

Add to Collection

Article Oncology

Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma

Jin Hou et al.

CANCER CELL (2014)

Add to Collection

Review Immunology

Regulation of type I interferon responses

Lionel B. Ivashkiv et al.

NATURE REVIEWS IMMUNOLOGY (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Reconstitution of the RIG-I Pathway Reveals a Signaling Role of Unanchored Polyubiquitin Chains in Innate Immunity

Wenwen Zeng et al.

CELL (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.